key: cord-0918812-3ae3o857 authors: SZABO, Balint Gergely; LAKATOS, Botond; BOBEK, Ilona; SZABO, Edina; SZLAVIK, Janos; VÁLYI-NAGY, István title: Invasive fungal infections among critically ill adult COVID-19 patients: first experiences from the national centre in Hungary date: 2021-08-14 journal: J Mycol Med DOI: 10.1016/j.mycmed.2021.101198 sha: 7c3a20a8cb09400533cec9da1039fda718fef181 doc_id: 918812 cord_uid: 3ae3o857 INTRODUCTION: : Data suggests that invasive fungal infections (IFI) might complicate COVID-19. Our goal was to describe characteristics of IFI among critically ill COVID-19 adults. METHODS: : A retrospective observational case-series analysis was done between March–July 2020. Consecutive patients with critical COVID-19 were eligible, and have been included when proven or putative/probable IFI could be confirmed during their course. For COVID-19 diagnosis, ECDC definitions and WHO severity criteria were followed. Candidaemia was diagnosed according to the ESCMID 2012 guideline. Invasive pulmonary aspergillosis (IPA) was defined following EORTC/MSG, ECMM/ISHAM and modified AspICU criteria. Outcome variables were rates of IFIs, in-hospital all-cause mortality, rate and time to negative respiratory SARS-CoV-2 PCR. RESULTS: : From 90 eligible patients, 20 (22.2%) fulfilled criteria for IFI. Incidence rate for IFI was 2.02 per 100 patient-days at ICU. Patients were mostly elderly males with significant comorbidities, requiring mechanical ventilation because of ARDS. IFI could be classified as candidaemia in 7/20 (40%), putative/probable IPA in 16/20 (80.0%). Isolated species of candidaemia episodes were Candida albicans (4/9, 44.4%), Candida glabrata (3/9, 33.3%), Candida parapsilosis (1/9, 11.1%), Candida metapsilosis (1/9, 11.1%). Mold isolates from lower respiratory tract were Aspergillus fumigatus, BAL galactomannan positivity was prevalent (16/20, 80.0%). Mortality was 12/20 (60.0%) with a median time to death of 31.0±37.0 (5–89) days. Only 9/20 (45.0%) patients reached SARS-CoV-2 PCR negativity after a median time of 20.0±12.0 (3–38) days. CONCLUSION: : In this small cohort of critically ill COVID-19 adults, morbidity and mortality related to invasive fungal infections proved to be significant. Data suggests that invasive fungal infections (IFI) might complicate COVID-19. Our goal was to describe characteristics of IFI among critically ill COVID-19 adults. A retrospective observational case-series analysis was done between March-July 2020. Consecutive patients with critical COVID-19 were eligible, and have been included when proven or putative/probable IFI could be confirmed during their course. For COVID-19 diagnosis, ECDC definitions and WHO severity criteria were followed. Candidaemia was diagnosed according to the ESCMID 2012 guideline. Invasive pulmonary aspergillosis (IPA) was defined following EORTC/MSG, ECMM/ISHAM and modified AspICU criteria. Outcome variables were rates of IFIs, in-hospital all-cause mortality, rate and time to negative respiratory SARS-CoV-2 PCR. From 90 eligible patients, 20 (22.2%) fulfilled criteria for IFI. Incidence rate for IFI was 2.02 per 100 patient-days at ICU. Patients were mostly elderly males with significant comorbidities, requiring mechanical ventilation because of ARDS. IFI could be classified as candidaemia in 7/20 (40%), putative/probable IPA in 16/20 (80.0%). Isolated species of candidaemia episodes were Candida albicans (4/9, 44.4%), Candida glabrata (3/9, 33.3%), Candida parapsilosis (1/9, 11.1%), Candida metapsilosis (1/9, 11.1%). Mold isolates from lower respiratory tract were Aspergillus fumigatus, BAL galactomannan positivity was prevalent (16/20, 80 .0%). Mortality was 12/20 (60.0%) with a median time to death of 31.0±37.0 (5-89) days. Only 9/20 (45.0%) patients reached SARS-CoV-2 PCR negativity after a median time of 20.0±12.0 (3-38) days. In this small cohort of critically ill COVID-19 adults, morbidity and mortality related to invasive fungal infections proved to be significant. by the highly virulent human coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). In its most severe forms, COVID-19 progresses to multi-systemic dysfunction, including acute respiratory distress syndrome (ARDS) and cytokine storm (CS). Data from the literature suggest that invasive fungal infections (IFI) might also be accounting for additional morbidity in critical COVID-19, especially in patients with the aforementioned complications [1] . Our aim was to assess the burden and characteristics of invasive fungal infections among critically ill adult COVID-19 patients hospitalized at our centre during the first 4 months of the pandemic. A retrospective, observational case-series analysis of adult patients hospitalized with COVID-19 at our centre between March and July 2020 was carried out. Our centre is the national referral institution of haematological and infectious diseases, and the main COVID-19 center of Hungary. The study was in accordance with the Helsinki Declaration, as well as national ethical standards. The study protocol was approved by the institutional review board. Consecutive patients with severe or critical COVID-19 were eligible for inclusion. Patient identification and selection was done using the hospital database and notes of infectious disease consultations. To overcome selectional bias, all severe or critically ill patients admitted to our intensive care unit (ICU) were assessed for inclusion by the study team, and a separate list containing data of fungal isolates from clinical specimens and fungal biomarker positivities has been generated for cross-checking. Patients were included if they had proven, probable or putative invasive fungal infection(s) during their clinical course with COVID-19 (see below). No a priori exclusion criteria were used. Per protocol, in-hospital follow-up was provided for each patient, post-discharge follow-up was not seeked. A database has been established for the study purpose by manual data extraction from hospital records, and anonymized transfer to a standardized case report form. Collected data were: 1) age and gender, 2) comorbidities, 3) length of stay (LOS), 4) clinical and radiological parameters at COVID-19 and IFI diagnosis (symptom onset, oxygen demand, Horowitz index, ARDS and CS, radiomorphology on chest X-ray or computed tomography [CT]), 5) laboratory parameters at COVID-19 and IFI diagnosis (blood leucocyte, absolute neutrophil granulocyte, lymphocyte and platelet counts, hemoglobin, CRP, procalcitonin, serum ferritin, high sensitivity troponin-I, serum interleukin-6, NT-proBNP, serum creatinine, LDH and Ddimer), 6) rate and time to negative respiratory SARS-CoV-2 polymerase chain reaction (PCR), 7) microbiological characteristics ( [2] . A suspected COVID-19 case is confirmed if SARS-CoV-2 nucleic acid is detected by PCR in a clinical specimen. COVID-19 severity is stratified per World Health Organization (WHO) criteria [3] . Non-infectious complications of critical COVID-19 disease were defined as ARDS and/or CS. ARDS is identified according to the 2012 Berlin criteria, CS is diagnosed by trends of clinical and laboratory parameters along with the HScore [4, 5] . IFI was defined if presence of a yeast or mold was proven by culture or non-culture based microbiological methods in a clinical sample obtained by a sterile procedure from a physiologically sterile site/fluid, along with a compatible clinical presentation. Candidaemia episodes were diagnosed if Candida sp. was recovered from ≥1 blood culture [6] . Cases of invasive pulmonary aspergillosis (IPA) are ascertained following the EORTC/MSG criteria in immunocompromised (proven or probable diagnosis) and modified AspICU criteria in immunocompetent patients (proven or putative diagnosis) [7] [8] [9] . In both systems, proven IPA is defined by microscopic analysis (histopathologic, Clinical outcome variables were rate and time to in-hospital all-cause mortality, and rates of invasive fungal infections. Virological outcomes were rate and time to negative SARS-CoV-2 respiratory PCR sampling. PCR negativity was defined if ≥2 consecutive respiratory PCR samples taken ≥48 hours were proven to be negative. Incidence regarding IFI was calculated by using cumulative data from hospital records. Continuous variables were expressed as median±interquartile range with minimum-maximum limits, categorical variables were expressed as absolute numbers (n) and percentages (%). Given the expected low incidence of IFIs, modelling of the primary outcome was not planned a priori. For reporting, we adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) Statement [13] . Outcomes, diagnostic and therapeutic approaches are shown in Table 3 and Table 4 . associated IPA from the literature, all patients had been mechanically ventilated at an ICU ward. Patients were predominantly elderly males (81%) with a history of chronic obstructive pulmonary disease (21%) and diabetes mellitus (27%) as comorbidities. The authors calculated an overall mortality of 67% among those affected, with Aspergillus fumigatus isolated from BAL or tracheal samples as the causative pathogen of IPA in most cases. Serum galactomannan positivity was low (23%), while respiratory galactomannan testing had a better yield (71%). Patients were diagnosed by using the AspICU algorithm [14] . In our cohort, we found a similar rate from serum, but tracheal sampling provided lower positivity compared to results of Antinori et al. Therefore, we cannot exclude a higher rate of false negative testing at our centre (eg. due to mucolytic agent use among patients not included in the final cohort). widely vary between centres. In a retrospective chart review done by Koehler [20] . Moreover, Antinori et al. observed a relatively high rate of candidemia (6.9%) among a cohort of 43 COVID-19 patients treated with tocilizumab at the ward or ICU, suggesting that IL-6 blockade might be associated with invasive yeast infections [21] . In our cohort, the rate of candidaemia was higher compared to literature data, possibly reflecting a broader risk factor burden and longer ICU hospitalization times. The choice of empirical antifungal was dominantly caspofungin, targeted fluconazole could be given in some cases. Our study has several limitations. Firstly, this was a case-series analysis done in a single centre. The relatively small sample size and the lack of a matching control group limits exact risk estimation of IFI among COVID-19 patients. Some patients had multiple infectious complications, and a definite cause of death could not be determined, as autopsies of COVID-19 patients were not routinely done during the first wave in Hungary. Some diagnostic uncertainties might have biased our results, eg. the higher rate of serum BDG might partially represent false positivity (eg. due to intravenous immunoglobuline, parenteral nutrition, gauze usage etc.). Exact body weights were not routinely documented at ICU, but presence of obesity based on clinical examination was archived. Finally, it could be challenging to 13 distinguish a colonization from a clinical infection with Aspergillus sp. in patients with COPD. Despite these limitations, we think that our study might underscore the importance of clinically relevant, potentially fatal invasive fungal diseases among COVID-19 patients. In this series of critically ill adult COVID-19 patients, invasive fungal infections including invasive pulmonary aspergillosis and candidaemia seemed to result in relevant morbidity and mortality burden. Further prospective data should be collected on this emerging subject. Funding: The article itself did not receive any external funding. BGSz received the EFOP- and invasive fungal infections included in the study. Total (n=20) Laboratory characteristics at COVID-19 diagnosis (median±IQR, min-max): -White blood cell count (x10 9 /L) -Neutrophil granulocyte count (x10 9 /L) -Lymphocyte count (x10 9l /) -Thrombocyte count (x10 9 Invasive fungal diseases during COVID-19: We should be prepared European Centre for Disease Prevention and Control. Case definition for coronavirus disease World Health Organization. Clinical management of COVID-19 Acute respiratory distress syndrome: the Berlin Definition COVID-19: consider cytokine storm syndromes and immunosuppression ESCMID guideline for the diagnosis and management of Candida diseases 2012: nonneutropenic adult patients A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Defining and managing COVID-19 ECMM/ISHAM consensus criteria for research and clinical guidance. The Lancet Infectious Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia Clinical Practice Guidelines by the Infectious Diseases Society of America and the The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia COVID-19 associated pulmonary aspergillosis COVID-19-associated Pulmonary Aspergillosis Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? COVID-19 and fungal co-infections: We must keep them in mind Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?